Serum Leptin and Adiponectin Concentration in Type 2 Diabetes Patients in the Short and Long Term Following Biliopancreatic Diversion

Obesity Surgery

Volumn 26, Issue 10, 2016, Pages 2442-2448

  Adami, Gian Franco ^a   Gradaschi, Raffaella ^b   Andraghetti, Gabriella ^a   Scopinaro, Nicola ^b   Cordera, Renzo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute insulin response; Adiponectin; Bariatric surgery; Leptin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEPTIN; ADIPOQ PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CYTOKINE PRODUCTION; DIABETIC PATIENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; BLOOD; MIDDLE AGED; TIME FACTOR;

ADIPONECTIN; ADULT; AGED; BILIOPANCREATIC DIVERSION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; OBESITY; POSTOPERATIVE PERIOD; TIME FACTORS;

EID: 84961198178     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-016-2126-z     Document Type: Article

References (44)

1. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. doi:10.1001/jama.2014.5988.
2. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56. doi:10.1016/j.amjmed.2008.09.041. e5.
3. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309(21):2250–61. doi:10.1001/jama.2013.4851.
4. Dixon JB, Zimmet P, Alberti KG, Rubino F, on behalf of the International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese type 2 diabetes. Surg Obes Relat Dis. 2011;7(4):433–47. doi:10.1016/j.soard.2011.05.013.
5. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36 Suppl 1:S11–66. doi:10.2337/dc13-S011.
6. Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–23. doi:10.1001/jama.299.3.316.
7. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84. discussion 84–5
8. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28(10):2406–11.
9. Beckman LM, Beckman TR, Sibley SD, et al. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. JPEN J Parenter Enteral Nutr. 2011;35(2):169–80. doi:10.1177/0148607110381403.
10. Falkén Y, Hellström PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227–35. doi:10.1210/jc.2010-2876.
11. Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–96. doi:10.1007/s11695-012-0621-4.
12. Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13(6):983–8. doi:10.1016/j.coph.2013.09.014.
13. Kohli R, Myronovych A, Tan BK, et al. Bile acid signaling: mechanism for bariatric surgery, cure for NASH? Dig Dis. 2015;33(3):440–6. doi:10.1159/000371699.
14. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8. doi:10.1038/nature13135.
15. Adami GF, Parodi RC, Papadia F, et al. Magnetic resonance spectroscopy facilitates assessment of intramyocellular lipid changes: a preliminary short-term study following biliopancreatic diversion. Obes Surg. 2005;15(9):1233–7.
16. 2: an integrative review of early studies. Obes Surg. 2010;20(6):776–90. doi:10.1007/s11695-010-0113-3.
17. Müller-Stich BP, Senft JD, Warschkow R, et al. Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg. 2015;261(3):421–9. doi:10.1097/SLA.0000000000001014.
18. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6(1):13–21.
19. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013;4:71. doi:10.3389/fendo.2013.00071.
20. Knights AJ, Funnell AP, Pearson RC, et al. Adipokines and insulin action: a sensitive issue. Adipocytes. 2014;3(2):88–96. doi:10.4161/adip.27552.
21. Faraj M, Havel PJ, Phélis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88(4):1594–602.
22. Salani B, Briatore L, Andraghetti G, et al. High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity (Silver Spring). 2006;14(9):1511–4.
23. Chen J, Pamuklar Z, Spagnoli A, et al. Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery. Surg Endosc. 2012;26(5):1476–80. doi:10.1007/s00464-011-2059-5.
24. Lindegaard KK, Jorgensen NB, Just R, et al. Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. Diabetol Metab Syndr. 2015;7:12. doi:10.1186/s13098-015-0012-9.
25. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22(9):936–46.
26. Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011;253(4):699–703. doi:10.1097/SLA.0b013e318203ae44.
27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
28. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5. doi:10.2337/dc09-9036.
29. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7):461–70. doi:10.1016/j.tips.2015.04.014.
30. Tilg H, Moschen AR. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol. 2014;28(4):599–610. doi:10.1016/j.bpg.2014.07.006.
31. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12. doi:10.1186/2047-783X-18-12.
32. Schwartz MW, Peskind E, Raskind M, et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996;2(5):589–93.
33. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.
34. Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014:658913. doi:10.1155/2014/658913.
35. Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metabolism. 2015;64(1):13–23. doi:10.1016/j.metabol.2014.09.010.
36. Butner KL, Nickols-Richardson SM, Clark SF, et al. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg. 2010;20(5):559–68. doi:10.1007/s11695-010-0089-z.
37. Herder C, Peltonen M, Svensson PA, et al. Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study. Diabetes Care. 2014;37(5):1401–9. doi:10.2337/dc13-1362.
38. Wroblewski E, Swidnicka-Siergiejko A, Hady HR, et al. Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies. Cytokine. 2016;77:56–62. doi:10.1016/j.cyto.2015.10.013.
39. Kotidis EV, Koliakos GG, Baltzopoulos VG, et al. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study. Obes Surg. 2006;16(11):1425–32.
40. Kopp HP, Krzyzanowska K, Möhlig M, et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes. 2005;29(7):766–71.
41. Fellici AC, Lambert G, Lima MM, et al. Surgical treatment of type 2 diabetes in subjects with mild obesity: mechanisms underlying metabolic improvements. Obes Surg. 2015;25(1):36–44. doi:10.1007/s11695-014-1377-9.
42. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36(8):2175–82. doi:10.2337/dc12-1596.
43. Scopinaro N, Camerini G, Papadia F, et al. Long term clinical and functional impact of biliopancreatic diversion on type 2 diabetes in morbidly and non morbidly obese patients. Surg Obes Relat Dis. 2015. doi:10.1016/j.soard.2015.12.011.
44. Hirsch FF, Pareja JC, Geloneze SR, et al. Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes. Obes Surg. 2012;22(6):910–7. doi:10.1007/s11695-012-0589-0.